Patents Assigned to SILENSEED LTD.
  • Patent number: 10006030
    Abstract: This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: June 26, 2018
    Assignee: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky
  • Publication number: 20170283803
    Abstract: This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.
    Type: Application
    Filed: July 14, 2015
    Publication date: October 5, 2017
    Applicant: SILENSEED LTD.
    Inventors: Amotz SHEMI, Elina ZORDE KHVALEVSKY
  • Patent number: 9764035
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Grant
    Filed: March 29, 2015
    Date of Patent: September 19, 2017
    Assignee: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Patent number: 9687500
    Abstract: Treatment of cancer by regional and prolonged release of one or more nucleotide-based agents is provided.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 27, 2017
    Assignee: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Publication number: 20150238517
    Abstract: Treatment of cancer by regional and prolonged release of one or more nucleotide-based agents is provided.
    Type: Application
    Filed: May 14, 2015
    Publication date: August 27, 2015
    Applicant: SILENSEED LTD.
    Inventors: Amotz SHEMI, Elina ZORDE KHVALEVSKY, Rachel MALKA GABAI
  • Publication number: 20150196648
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Application
    Filed: March 29, 2015
    Publication date: July 16, 2015
    Applicant: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Patent number: 9080173
    Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: July 14, 2015
    Assignee: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky
  • Publication number: 20150050341
    Abstract: The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
    Applicant: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky
  • Publication number: 20130142875
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Application
    Filed: November 14, 2012
    Publication date: June 6, 2013
    Applicant: SILENSEED LTD.
    Inventor: SILENSEED LTD.
  • Publication number: 20130122096
    Abstract: Polymeric implants containing microparticles and nanoparticles, delivery of microparticles and nanoparticles from a polymeric implant is provided.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: SILENSEED LTD.
    Inventor: SILENSEED LTD.
  • Publication number: 20110275891
    Abstract: The present invention relates to a system and method for the delivery of a treatment element, and in particular, to such a system and method in which an implantable treatment element is implanted at a target site.
    Type: Application
    Filed: January 27, 2010
    Publication date: November 10, 2011
    Applicant: SILENSEED LTD.
    Inventor: Amotz Shemi
  • Publication number: 20110195123
    Abstract: Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs.
    Type: Application
    Filed: June 28, 2009
    Publication date: August 11, 2011
    Applicant: SILENSEED LTD.
    Inventor: Amotz Shemi